Robin Kramer - Feb 12, 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Chief Accounting Officer
Signature
/s/ Wendell Taylor, attorney-in-fact for Robin Kramer
Stock symbol
BIIB
Transactions as of
Feb 12, 2022
Transactions value $
-$36,695
Form type
4
Date filed
2/15/2022, 03:13 PM
Previous filing
Feb 14, 2022
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +99 +7.31% $0.00 1.45K Feb 12, 2022 Direct
transaction BIIB Common Stock Tax liability -$7.51K -35 -2.41% $214.59 1.42K Feb 12, 2022 Direct
transaction BIIB Common Stock Options Exercise $0 +176 +12.41% $0.00 1.59K Feb 12, 2022 Direct
transaction BIIB Common Stock Tax liability -$10.9K -51 -3.2% $214.59 1.54K Feb 12, 2022 Direct
transaction BIIB Common Stock Tax liability -$18.2K -85 -5.51% $214.59 1.46K Feb 12, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -99 -34.38% $0.00 189 Feb 12, 2022 Common Stock 99 $0.00 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -189 -100% $0.00* 0 Feb 12, 2022 Common Stock 189 $0.00 Direct F2, F3
transaction BIIB Restricted Stock Unit Options Exercise $0 -176 -17.46% $0.00 832 Feb 12, 2022 Common Stock 176 $0.00 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -326 -39.18% $0.00 506 Feb 12, 2022 Common Stock 326 $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.
F2 The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.